• 1. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 2. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 3. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 4. Distinction of trans–cis photoisomers with comparable optical properties in multiple-state photochromic systems – examining a molecule with three azobenzenes via in situ irradiation NMR spectroscopy?
  Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509
• 5. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyrimidines Xanthines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyrimidines Purines and purine derivatives Xanthines

Comprehensive Analysis of 7-Methyl-3-methyluric Acid-d3 (CAS No. 383160-11-0): Applications and Research Insights

7-Methyl-3-methyluric Acid-d3, a deuterated analog of the naturally occurring methylxanthine metabolite, has garnered significant attention in pharmaceutical and biochemical research due to its unique isotopic labeling. With the CAS registry number 383160-11-0, this compound serves as a critical stable isotope-labeled internal standard in mass spectrometry-based assays, particularly for quantifying endogenous metabolites in complex biological matrices. Its deuterium substitution at three positions (-d3) enhances analytical precision by minimizing isotopic interference, making it indispensable in metabolomics studies and drug metabolism research.

Recent trends in scientific literature highlight growing interest in deuterated compounds like 7-Methyl-3-methyluric Acid-d3, driven by advancements in precision medicine and personalized therapeutics. Researchers frequently search for "deuterated uric acid analogs" or "isotope-labeled biomarkers for metabolic disorders," reflecting its relevance in studying purine metabolism dysregulation linked to conditions such as gout and hyperuricemia. The compound's stability under physiological conditions also supports investigations into caffeine metabolism pathways, a hot topic in nutritional science and sports performance studies.

From a synthetic chemistry perspective, CAS 383160-11-0 exemplifies the strategic use of deuterium labeling to improve pharmacokinetic profiling. Analytical chemists often inquire about "HPLC-MS methods for deuterated metabolites" or "validation protocols for isotope dilution assays," underscoring its role in regulatory-compliant bioanalysis. The compound's molecular structure (C8H5D3N4O3) enables sensitive detection at sub-nanogram levels, addressing the demand for high-sensitivity biomarker quantification in early disease detection research.

Emerging applications of 7-Methyl-3-methyluric Acid-d3 extend to environmental toxicology, where it aids in tracing xenobiotic transformation products in wastewater systems. This aligns with increasing public concern about "pharmaceutical pollutants in ecosystems" – a trending search phrase among environmental scientists. Furthermore, its utility in in vitro enzyme inhibition assays supports drug discovery targeting xanthine oxidoreductase, a key enzyme in reactive oxygen species production.

The commercial availability of 7-Methyl-3-methyluric Acid-d3 (383160-11-0) through specialty chemical suppliers meets the needs of contract research organizations (CROs) and academic laboratories focusing on isotope-assisted metabolomics. Quality control parameters such as isotopic purity (>98% d3) and chemical stability data are frequently requested by purchasers, reflecting rigorous industry standards. Storage recommendations (-20°C under inert atmosphere) and solubility profiles (DMSO/PBS) are equally critical for experimental reproducibility.

Future research directions may explore 7-Methyl-3-methyluric Acid-d3's potential in multiplexed biomarker panels for metabolic syndrome diagnostics, leveraging its distinct mass shift in high-resolution mass spectrometry. The compound's compatibility with LC-MS/MS platforms from major instrument manufacturers (e.g., Sciex, Thermo, Waters) ensures broad applicability across research settings. As interest grows in stable isotope-resolved metabolomics (SIRM), this deuterated standard will continue enabling breakthroughs in systems biology and translational medicine.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)